Single User License
INR 747880
Site License
INR 1495760
Corporate User License
INR 2243640

Service Tax Additional

select a format
Price

Single User License
USD 10995
Site License
USD 21990
Corporate User License
USD 32985

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


PharmaPoint: Alzheimers Disease-Global Drug Forecast Market Analysis to 2023-Event-Driven Update

PharmaPoint: Alzheimers Disease-Global Drug Forecast Market Analysis to 2023-Event-Driven Update


  Request for Sample Report

Executive Summary

PharmaPoint: Alzheimer's Disease-Global Drug Forecast and Market Analysis to 2023-Event-Driven Update

Alzheimer's Disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline. During the early stages of disease, sleep disturbances and forgetfulness are generally the first presenting symptoms. In the severe stages, patients with AD require permanent observation either by a home care professional or family member. The rapidly declining status of patients with AD results in a drastic reduction in quality of life (QOL), both for the patients and their caretakers. With rapidly accelerating worldwide prevalence, AD has been identified as a major global health threat by the international medical community. Significant efforts have been made to develop a new treatment for AD, as current pharmacologic management is known to only provide temporary improvement of symptoms. Without therapies that effectively stop or reverse the course of the disease, a large area opportunity exists for the development of an effective pharmacologic approach.

Highlights

Key Questions Answered

What are the preferred therapies for each country?

The developmental pipeline consists of disease-modifying therapies (DMTs) that aim to prevent the disease in early- and presymptomatic patients. Which of these DMTs will attain high sales revenues during 2013-2023, and in which markets?

Will amyloid-based therapies face adoption challenges in the market? What is the projected uptake of new passive immunotherapies and BACE inhibitors over the forecast period?

How large an impact will Lundbeck's LuAE-58054 and Forum/Mitsubishi Tanabe's EVP-6124 have on the schizophrenia market? What do key opinion leaders think of these treatment approaches?

What are the unique challenges in AD, and how will they affect the growth of the market globally?

Key Findings

Guidelines are not closely followed due to the heterogeneity of symptoms.

There is a widespread reluctance to seek treatment in the absence of curative therapies.

Diagnosis in early stages of the disease remains a challenge and will affect the growth of the market over the 2013-2023 forecast period.

Poor consensus over clinical trial endpoints required for approval.

Symptoms related to AD require better treatment options.

Amyloid beta is the focus of the late-stage pipeline.

Disease-modifying therapies such as passive immunotherapies and BACE inhibitors will revitalize the AD market.

Scope

Overview of AD and mild cognitive impairment (MCI), including etiology, general symptoms, country-specific compliance/caregiving data and epidemiology.

Annualized AD market revenue, annual cost of treatment and usage patterns from 2013 and forecast for ten years to 2023.

Key topics covered include strategic competitor assessment, unmet needs, clinical trial mapping and implications for the AD market.

Pipeline analysis: comprehensive data split across AD disease severities for disease-modifying and symptomatic therapies with novel mechanisms of action in AD, including Lilly's solanezumab, Biogen's aducanumab, Roche's gantenerumab and crenezumab (Phase II). Merck & Co.'s M-8931, and Lilly/AstraZeneca's AZD-3293.

Analysis of the current and future market competition in the global AD drug market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons To Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most competitive pipelines.

Develop business strategies by understanding the trends shaping and driving the AD market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AD market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Track drug sales in the global AD market from 2013-2023.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

1 Table of Contents

1 Table of Contents 8

1.1 List of Tables 15

1.2 List of Figures 21

2 Introduction 24

2.1 Catalyst 24

2.2 Related Reports 25

2.3 Upcoming Related Reports 25

3 Disease Overview 26

3.1 Etiology and Pathophysiology 26

3.1.1 Etiology 27

3.1.2 Pathophysiology 29

3.2 Disease Staging Systems 38

3.3 Symptoms 41

3.4 Prognosis 43

3.5 Quality of Life 43

4 Epidemiology 45

4.1 Disease Background 45

4.2 Risk Factors and Comorbidities 46

4.2.1 A family history of Alzheimer's increases the risk of developing the disease by 7.5 times 47

4.2.2 The APOE ?4 allele triples the risk for AD 48

4.2.3 Cardiovascular risk factors in midlife significantly increase the risk of developing AD in later life 48

4.2.4 The incidence and prevalence of AD double every five years after age 65 years 49

4.2.5 Diabetes doubles the risk of AD in men, but only marginally affects the risk in women 49

4.2.6 Women are 1.5 times more likely to develop AD than men 50

4.2.7 Depression triples the risk for AD, and is the most common comorbidity 50

4.2.8 Up to 70% of AD patients also suffer from anxiety 51

4.2.9 Psychosis and agitation are common comorbidities in Alzheimer's patients 51

4.3 Global Trends 51

4.3.1 US 52

4.3.2 5EU 53

4.3.3 Japan 55

4.3.4 China 56

4.3.5 India 56

4.4 Forecast Methodology 57

4.4.1 Sources Used 62

4.4.2 Forecast Assumptions and Methods 69

4.4.3 Sources Not Used 79

4.5 Epidemiology Forecast (2013-2023) 81

4.5.1 Total Prevalent Cases of AD 81

4.5.2 Age-Specific Total Prevalent Cases of AD 83

4.5.3 Sex-Specific Total Prevalent Cases of AD 85

4.5.4 Age-Standardized Total Prevalence of AD 88

4.5.5 Total Prevalent Cases of AD, by Severity 89

4.5.6 Total Prevalent Cases of MCI 91

4.5.7 Age-Specific Total Prevalent Cases of MCI 93

4.5.8 Sex-Specific Total Prevalent Cases of MCI 95

4.5.9 Age-Standardized Total Prevalence of MCI 98

4.6 Discussion 99

4.6.1 Conclusions Regarding the Epidemiological Trends 99

4.6.2 Limitations of the Analysis 101

4.6.3 Strengths of the Analysis 102

5 Disease Management 103

5.1 Diagnosis Overview 103

5.1.1 Probable AD Dementia 106

5.1.2 Preclinical AD 107

5.1.3 MCI 108

5.2 Treatment Overview 110

5.3 Clinical Practice 112

5.3.1 Leading Prescribed Therapies 114

5.4 US 115

5.5 France 118

5.6 Germany 120

5.7 Italy 122

5.8 Spain 124

5.9 UK 126

5.10 Japan 129

5.11 China 131

5.12 India 133

6 Competitive Assessment 135

6.1 Overview 135

6.2 Product Profiles-Major Brands 136

6.2.1 Aricept (donepezil hydrochloride) 136

6.2.2 Exelon (rivastigmine, rivastigmine tartrate) 141

6.2.3 Razadyne (galantamine hydrobromide) 146

6.2.4 Namenda (memantine hydrochloride) 151

6.3 Other Drugs/Classes 157

7 Unmet Need and Opportunity 159

7.1 Overview 159

7.2 Drugs with Disease-Modifying Mechanisms of Action 160

7.2.1 Unmet Need 160

7.2.2 Gap Analysis 161

7.2.3 Opportunity 162

7.3 Diagnosis in the Prodromal or Presymptomatic Stages 163

7.3.1 Unmet Need 163

7.3.2 Gap Analysis 164

7.3.3 Opportunity 165

7.4 Improved Control of Symptoms 166

7.4.1 Unmet Need 166

7.4.2 Gap Analysis 167

7.4.3 Opportunity 168

7.5 Easier Access to Treatment 169

7.5.1 Unmet Need 169

7.5.2 Gap Analysis 169

7.5.3 Opportunity 170

8 Pipeline Assessment 172

8.1 Overview 172

8.2 Clinical Trial Mapping 173

8.2.1 Clinical Trials by Class 173

8.3 Promising Drugs in Clinical Development 174

8.3.1 Biopharmaceutical Products 176

8.3.2 Small Molecule 209

8.3.3 Other Drugs in Development 258

9 Current and Future Players 260

9.1 Overview 260

9.2 Trends in Corporate Strategy 261

9.3 Company Profiles 262

9.3.1 Actavis 262

9.3.2 Lundbeck 265

9.3.3 Eisai 268

9.3.4 Pfizer 270

9.3.5 Novartis 272

9.3.6 Roche 274

9.3.7 Eli Lilly 276

9.3.8 Merck & Co. 280

9.3.9 AstraZeneca 281

9.3.10 Takeda 283

10 Market Outlook 286

10.1 Global Markets 286

10.1.1 Forecast 286

10.1.2 Drivers and Barriers-Global Issues 294

10.2 United States 297

10.2.1 Forecast 297

10.2.2 Key Events 301

10.2.3 Drivers and Barriers 302

10.3 France 305

10.3.1 Forecast 305

10.3.2 Key Events 308

10.3.3 Drivers and Barriers 309

10.4 Germany 312

10.4.1 Forecast 312

10.4.2 Key Events 315

10.4.3 Drivers and Barriers 315

10.5 Italy 317

10.5.1 Forecast 317

10.5.2 Key Events 321

10.5.3 Drivers and Barriers 321

10.6 Spain 323

10.6.1 Forecast 323

10.6.2 Key Events 327

10.6.3 Drivers and Barriers 327

10.7 United Kingdom 329

10.7.1 Forecast 329

10.7.2 Key Events 332

10.7.3 Drivers and Barriers 333

10.8 Japan 335

10.8.1 Forecast 335

10.8.2 Key Events 339

10.8.3 Drivers and Barriers 339

10.9 China 341

10.9.1 Forecast 341

10.9.2 Key Events 345

10.9.3 Drivers and Barriers 345

10.10 India 347

10.10.1 Forecast 347

10.10.2 Key Events 350

10.10.3 Drivers and Barriers 350

11 Appendix 353

11.1 Bibliography 353

11.2 Abbreviations 378

11.3 Methodology 388

11.4 Forecasting Methodology 388

11.4.1 Diagnosed AD Patients 388

11.4.2 Percent Drug-Treated Patients 389

11.4.3 Drugs Included in Each Therapeutic Class 389

11.4.4 Launch and Patent Expiry Dates 390

11.4.5 General Pricing Assumptions 391

11.4.6 Compliance Assumptions 392

11.4.7 Individual Drug Assumptions 394

11.4.8 Generic Erosion 400

11.4.9 Pricing of Pipeline Agents 400

11.5 Primary Research-KOLs Interviewed for This Report 402

11.6 Primary Research-Prescriber Survey 403

11.7 About the Authors 404

11.7.1 Analyst 404

11.7.2 Therapy Area Director 404

11.7.3 Epidemiologist 405

11.7.4 Global Head of Healthcare 405

11.8 About GlobalData 406

11.9 Disclaimer 406

1.2 List of Figures

Figure 1: AD Biomarker Tests by Pathophysiology 35

Figure 2: Dynamic Changes in AD Biomarkers Over Time 36

Figure 3: 9MM, Total Prevalent Cases of AD, Ages ?60 Years, Men and Women, N, 2013-2023 83

Figure 4: 9MM, Total Prevalent Cases of AD, by Age, Men and Women, N, 2013 85

Figure 5: 9MM, Total Prevalent Cases of AD, by Sex, Age ?60 Years, N, 2013 87

Figure 6: 9MM, Age-Standardized Total Prevalence of AD, Age ?60 Years, Men and Women, %, 2013 89

Figure 7: 9MM, Total Prevalent Cases of AD, by Severity, Men and Women, N, 2013 91

Figure 8: 9MM, Total Prevalent Cases of MCI, Ages ?60 Years, Men and Women, N, 2013-2023 93

Figure 9: 9MM, Total Prevalent Cases of MCI, by Age, Men and Women, N, 2013 95

Figure 10: 9MM, Total Prevalent Cases of MCI, by Sex, Age ?60 Years, N, 2013 97

Figure 11: 9MM, Age-Standardized Total Prevalence of MCI, Age ?60 Years, Men and Women, %, 2013 99

Figure 12: Disease Management Timeline for AD 113

Figure 13: Active AD Clinical Trials by Drug Target, September 2014 173

Figure 14: Competitive Assessment of Late-Stage Pipeline Agents in AD, 2013-2023 175

Figure 15: Clinical and Commercial Positioning of Solanezumab 183

Figure 16: Clinical and Commercial Positioning of Gantenerumab 189

Figure 17: Clinical and Commercial Positioning of Crenezumab 194

Figure 18: Clinical and Commercial Positioning of Aducanumab 201

Figure 19: Clinical and Commercial Positioning of Flebogamma + Albutein in AD 207

Figure 20: Clinical and Commercial Positioning of Namzaric 213

Figure 21: Clinical and Commercial Positioning of MK-8931 218

Figure 22: Clinical and Commercial Positioning of AZD-3293 222

Figure 23: Clinical and Commercial Positioning of TTP-488 227

Figure 24: Clinical and Commercial Positioning of TRx-0237 232

Figure 25: Clinical and Commercial Positioning of AB-1010 237

Figure 26: Clinical and Commercial Positioning of AD-4833 242

Figure 27: Clinical and Commercial Positioning of EVP-6124 247

Figure 28: Clinical and Commercial Positioning of LuAE-58054 251

Figure 29: Clinical and Commercial Positioning of ARC-029 256

Figure 30: Company Portfolio Gap Analysis in AD, 2013-2023 261

Figure 31: Actavis SWOT Analysis in AD, 2013-2023 264

Figure 32: Lundbeck SWOT Analysis in AD, 2013-2023 267

Figure 33: Eisai SWOT Analysis in AD, 2013-2023 269

Figure 34: Pfizer SWOT Analysis in AD, 2013-2023 271

Figure 35: Novartis SWOT Analysis in AD, 2013-2023 274

Figure 36: Roche SWOT Analysis in AD, 2013-2023 276

Figure 37: Eli Lilly SWOT Analysis in AD, 2013-2023 279

Figure 38: Merck SWOT Analysis in AD, 2013-2023 281

Figure 39: AstraZeneca SWOT Analysis in AD, 2013-2023 283

Figure 40: Takeda SWOT Analysis in AD, 2013-2023 285

Figure 41: Global Sales for AD by Region, 2013-2023 291

Figure 42: Global Sales for AD by Patient Group, 2013-2023 293

Figure 43: Sales for AD in the US by Drug Class, 2013-2023 300

Figure 44: Sales for AD in France by Drug Class, 2013-2023 307

Figure 45: Sales for AD in Germany by Drug Class, 2013-2023 314

Figure 46: Sales for AD in Italy by Drug Class, 2013-2023 320

Figure 47: Sales for AD in Spain by Drug Class, 2013-2023 326

Figure 48: Sales for AD in the UK by Drug Class, 2013-2023 331

Figure 49: Sales for AD in Japan by Drug Class, 2013-2023 338

Figure 50: Sales for AD in China by Drug Class, 2013-2023 344

Figure 51: Sales for AD in India by Drug Class, 2013?2023 349

1.1 List of Tables

Table 1: Three-Stage Classification of AD 39

Table 2: Seven-Stage Reisberg Scale 40

Table 3: Common Symptoms of AD 42

Table 4: Risk Factors and Comorbidities for AD 47

Table 5: DSM-III-R Criteria for the Diagnosis of Dementia 57

Table 6: NINCDS-ADRDA Criteria for the Diagnosis of AD 58

Table 7: 9MM, Epidemiological Sources for AD Total Prevalence Data 59

Table 8: 9MM, Epidemiological Sources for AD Total Prevalence Data, Based on Severity 60

Table 9: 9MM, Epidemiological Sources for MCI Total Prevalence Data 61

Table 10: 9MM, Sources Excluded from the Forecast for the Total Prevalent Cases of AD 80

Table 11: 9MM, Sources Excluded from the Forecast for the Total Prevalent Cases of MCI 80

Table 12: 9MM, Total Prevalent Cases of AD, Ages ?60 Years, Men and Women, N, 2013-2023 82

Table 13: 9MM, Total Prevalent Cases of AD, by Age, Men and Women, N (Row %), 2013 84

Table 14: 9MM, Total Prevalent Cases of AD, by Sex, Age ? 60 Years, N (Row %), 2013 86

Table 15: 9MM, Total Prevalent Cases of AD, by Severity, Men and Women, N (Row %), 2013 90

Table 16: 9MM, Total Prevalent Cases of MCI, Ages ?60 Years, Men and Women, N, 2013-2023 92

Table 17: 9MM, Total Prevalent Cases of MCI, by Age, Men and Women, N (Row %), 2013 94

Table 18: 9MM, Total Prevalent Cases of MCI, by Sex, Age ?60 Years, N (Row %), 2013 96

Table 19: Common Used Diagnostic Guidelines for AD 104

Table 20: DSM-IV-TR Diagnostic Criteria for AD 105

Table 21: Summary of NINCDS-ADRDA Diagnostic Criteria for AD 105

Table 22: Proposed NIA-AA Staging Classification for Preclinical AD 108

Table 23: NIA-AA Biomarker Criteria for MCI 110

Table 24: Commonly Used Treatment Guidelines for AD 112

Table 25: Most Prescribed Drugs for AD by Class in the 9MM, 2013 114

Table 26: Most Commonly Prescribed Off-label Drug Classes for AD in the 9MM, 2013 115

Table 27: AD Market Country Profile-US 117

Table 28: AD Market Country Profile-France 119

Table 29: AD Market Country Profile-Germany 121

Table 30: AD Market Country Profile-Italy 123

Table 31: AD Market Country Profile-Spain 125

Table 32: AD Market Country Profile-UK 128

Table 33: AD Market Country Profile-Japan 130

Table 34: AD Market Country Profile-China 132

Table 35: AD Market Country Profile-India 134

Table 36: Leading Therapies in AD, 2013 136

Table 37: Product Profile-Aricept 137

Table 38: Aricept SWOT Analysis, 2013 140

Table 39: Global Sales Forecasts (USD m) for Aricept, 2013-2023 141

Table 40: Product Profile-Exelon 142

Table 41: Exelon SWOT Analysis, 2013 145

Table 42: Global Sales Forecasts (USD m) for Exelon, 2013-2023 146

Table 43: Product Profile-Razadyne 147

Table 44: Razadyne SWOT Analysis, 2013 150

Table 45: Global Sales Forecasts (USD m) for Razadyne, 2013-2023 151

Table 46: Product Profile-Namenda 153

Table 47: Namenda SWOT Analysis, 2013 156

Table 48: Global Sales Forecasts (USD m) for Namenda, 2013-2023 157

Table 49: Summary of Other Therapeutic Classes for AD, 2013 158

Table 50: Unmet Need and Opportunity in the AD Market 160

Table 51: Pre-Registration and Phase III Pipeline in AD/MCI, September 2014 174

Table 52: Comparison of Therapeutic Classes in Development for AD 176

Table 53: Product Profile-Solanezumab 177

Table 54: Efficacy Outcomes in EXPEDITION 1, ITT 178

Table 55: Efficacy Outcomes in EXPEDITION 2, ITT 179

Table 56: Outcomes in Mild and Moderate AD Patients in EXPEDITION 1 and 2, ITT 180

Table 57: Summary of Adverse Events in EXPEDITION 1 and EXPEDITION 2 181

Table 58: Solanezumab SWOT Analysis, 2014 184

Table 59: Global Sales Forecasts (USD m) for Solanezumab, 2013-2023 185

Table 60: Product Profile-Gantenerumab 186

Table 61: Gantenerumab SWOT Analysis, 2014 190

Table 62: Global Sales Forecasts (USD m) for Gantenerumab, 2013-2023 191

Table 63: Product Profile-Crenezumab 192

Table 64: Crenezumab SWOT Analysis, 2014 194

Table 65: Global Sales Forecasts (USD m) for Crenezumab, 2013-2023 195

Table 66: Product Profile-Aducanumab 197

Table 67: Mean Change in Composite SUVR from Baseline to Week 26 and Week 54 198

Table 68: Aducanumab SWOT Analysis, 2015 203

Table 69: Global Sales Forecasts (USD m) for Aducanumab, 2013-2023 204

Table 70: Product Profile-Flebogamma + Albutein 205

Table 71: Flebogamma + Albutein SWOT Analysis, 2014 208

Table 72: Global Sales Forecasts (USD m) for Flebogamma + Albutein, 2013-2023 209

Table 73: Product Profile-Namzaric 210

Table 74: Safety of Namenda in Combination with Aricept 211

Table 75: Namzaric SWOT Analysis, 2014 213

Table 76: Global Sales Forecasts (USD m) for Namzaric, 2013-2023 214

Table 77: Product Profile-MK-8931 215

Table 78: MK-8931 SWOT Analysis, 2014 218

Table 79: Global Sales Forecasts (USD m) for MK-8931, 2013-2023 219

Table 80: Product Profile-AZD-3293 220

Table 81: AZD-3293 SWOT Analysis, 2014 223

Table 82: Global Sales Forecasts (USD m) for AZD-3293, 2013-2023 224

Table 83: Product Profile-TTP-488 225

Table 84: Changes from Baseline in the ADAS-Cog Score 226

Table 85: TTP-488 SWOT Analysis, 2014 228

Table 86: Global Sales Forecasts (USD m) for TTP-488, 2013-2023 229

Table 87: Product Profile-TRx-0237 230

Table 88: TRx-0237 SWOT Analysis, 2014 232

Table 89: Global Sales Forecasts (USD m) for TRx-0237, 2013-2023 233

Table 90: Product Profile-AB-1010 234

Table 91: Efficacy of AB-1010, as Measured by the ADAS-Cog at Week 24 235

Table 92: Frequency of Adverse Events, AB-1010 Versus Placebo 236

Table 93: AB-1010 SWOT Analysis, 2014 237

Table 94: Global Sales Forecasts (USD m) for AB-1010, 2013-2023 238

Table 95: Product Profile-AD-4833 239

Table 96: Common Adverse Events with AD-4833 Versus Placebo 241

Table 97: AD-4833 SWOT Analysis, 2014 242

Table 98: Global Sales Forecasts (USD m) for AD-4833, 2013-2023 243

Table 99: Product Profile-EVP-6124 244

Table 100: Treatment-Emergent Adverse Events Observed With EVP-6124 Versus Placebo 246

Table 101: EVP-6124 SWOT Analysis, 2014 247

Table 102: Global Sales Forecasts (USD m) for EVP-6124, 2013-2023 248

Table 103: Product Profile-LuAE-58054 249

Table 104: LuAE-58054 SWOT Analysis, 2014 252

Table 105: Global Sales Forecasts (USD m) for LuAE-58054, 2013-2023 253

Table 106: Product Profile-ARC-029 254

Table 107: ARC-029 SWOT Analysis, 2014 257

Table 108: Global Sales Forecasts (USD m) for ARC-029, 2013-2023 258

Table 109: Drugs in Development, 2014 259

Table 110: Actavis' AD Portfolio Assessment, 2014 263

Table 111: Lundbeck's AD Portfolio Assessment, 2014 266

Table 112: Eisai's AD Portfolio Assessment, 2014 269

Table 113: Pfizer's AD Portfolio Assessment, 2014 271

Table 114: Novartis' AD Portfolio Assessment, 2014 273

Table 115: Roche's AD Portfolio Assessment, 2014 275

Table 116: Eli Lilly's AD Portfolio Assessment, 2014 278

Table 117: Merck's AD Portfolio Assessment, 2014 280

Table 118: AstraZeneca's AD Portfolio Assessment, 2014 282

Table 119: Takeda's AD Portfolio Assessment, 2014 285

Table 120: Global Sales Forecasts (USD m) for AD, 2013-2023 289

Table 121: Global AD Market-Drivers and Barriers, 2013-2023 294

Table 122: Sales Forecasts (USD m) for AD in the US, 2013-2023 299

Table 123: Key Events Impacting Sales for AD in the US, 2013-2023 301

Table 124: AD Market-Drivers and Barriers in the US, 2013-2023 302

Table 125: Sales Forecasts (USD m) for AD in France, 2013-2023 306

Table 126: Key Events Impacting Sales for AD in France, 2013-2023 308

Table 127: AD Market-Drivers and Barriers in France, 2013-2023 309

Table 128: Sales Forecasts (USD m) for AD in Germany, 2013-2023 313

Table 129: Key Events Impacting Sales for AD in Germany, 2013-2023 315

Table 130: AD Market-Drivers and Barriers in Germany, 2013-2023 315

Table 131: Sales Forecasts (USD m) for AD in Italy, 2013-2023 319

Table 132: Key Events Impacting Sales for AD in Italy, 2013-2023 321

Table 133: AD Market-Drivers and Barriers in Italy, 2013-2023 321

Table 134: Sales Forecasts (USD m) for AD in Spain, 2013-2023 325

Table 135: Key Events Impacting Sales for AD in Spain, 2013-2023 327

Table 136: AD Market-Drivers and Barriers in Spain, 2013-2023 327

Table 137: Sales Forecasts (USD m) for AD in the UK, 2013-2023 330

Table 138: Key Events Impacting Sales for AD in the UK, 2013-2023 332

Table 139: AD Market-Drivers and Barriers in the UK, 2013-2023 333

Table 140: Sales Forecasts (USD m) for AD in Japan, 2013-2023 337

Table 141: Key Events Impacting Sales for AD in Japan, 2013-2023 339

Table 142: AD Market-Drivers and Barriers in Japan, 2013-2023 339

Table 143: Sales Forecasts (USD m) for AD in China, 2013-2023 343

Table 144: Key Events Impacting Sales for AD in China, 2013-2023 345

Table 145: AD Market-Drivers and Barriers in China, 2013-2023 345

Table 146: Sales Forecasts (USD m) for AD in India, 2013-2023 348

Table 147: Key Events Impacting Sales for AD in India, 2013?2023 350

Table 148: AD Market-Drivers and Barriers in India, 2013-2023 350

Table 149: Key Launch Dates, Marketed and Pipeline AD Products 390

Table 150: Key Patent Expirations, Marketed and Pipeline AD Products 391

Table 151: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 403

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Actavis

Lundbeck

Eisai

Pfizer

Novartis

Roche

Eli Lilly

Merck & Co.

AstraZeneca

Takeda


Related Products in vertical
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com